Spaide and Vavvas aimed to evaluate available rationale and outcomes of randomized trial results for complement inhibition for geographic atrophy. Data from recently completed randomized trials of complement inhibition, particularly for pegcetacoplan and avacincaptad pegol, were evaluated for both the outcome, area of autofluorescence loss, and functional vision tests. They concluded that both avacincaptad pegol and pegcetacoplan show significant differences compared with sham in autofluorescence imaging but no benefit in visual function at 12 and 24 months, respectively.
Spaide RF, Vavvas DG. Complement Inhibition for Geographic Atrophy: Review of Salient Functional Outcomes and Perspective. Retina. 2023;43:1064-1069. https://pubmed.ncbi.nlm.nih.gov/36996460/
